We appreciated reading the eloquent editorial from Beasley et al. , who make a cogent evidence-based case for using budesonide/formoterol (BUD/FM) on demand (p.r.n.) as the preferred asthma reliever, in keeping with the latest GINA guidelines. They proffer what appears at first sight to be a pragmatic stepwise treatment algorithm and associated action plan for using BUD/FM p.r.n. as anti-inflammatory reliever (AIR)±maintenance therapy across Global Initiative for Asthma steps 1 to 3.